Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death

Cancers

Mélody Caillot¹  Brigitte Sola¹  Frédéric Mazurier²  Hassan Dakik² 

[1] Normandie University, INSERM, Université de Caen, F-14000 Caen, France;Université de Tours, GICC EA7501, CNRS, F-3700 Tours, France;

关键词: multiple myeloma;    ROS;    antioxidant enzyme;    proteasome inhibitor;    NOX;    mitochondria;   

DOI  :  10.3390/cancers13102411

来源: DOAJ

【 摘 要 】

Multiple myeloma (MM) is a common hematological disease characterized by the accumulation of clonal malignant plasma cells in the bone marrow. Over the past two decades, new therapeutic strategies have significantly improved the treatment outcome and patients survival. Nevertheless, most MM patients relapse underlying the need of new therapeutic approaches. Plasma cells are prone to produce large amounts of immunoglobulins causing the production of intracellular ROS. Although adapted to high level of ROS, MM cells die when exposed to drugs increasing ROS production either directly or by inhibiting antioxidant enzymes. In this review, we discuss the efficacy of ROS-generating drugs for inducing MM cell death and counteracting acquired drug resistance specifically toward proteasome inhibitors.

【 授权许可】

Unknown